Skip to Content

Cholesteryl Ester Storage Disease and Wolman Disease

(Wolman's Disease)


Matt Demczko

, MD, Sidney Kimmel Medical College of Thomas Jefferson University

Last full review/revision Apr 2020| Content last modified Apr 2020

Cholesteryl ester storage disease and Wolman disease are sphingolipidoses, an inherited disorder of metabolism, caused by lysosomal acid lipase deficiency resulting in hyperlipidemia and hepatomegaly.

For more information, see tables Sphingolipidosis and Other Lipidoses.

See also Approach to the Patient With a Suspected Inherited Disorder of Metabolism.

These diseases are rare, autosomal recessive disorders that result in accumulation of cholesteryl esters and triglycerides, mainly in lysosomes of histiocytes, resulting in foam cells in the liver, spleen, lymph nodes, and other tissues. Serum low-density lipoprotein (LDL) is usually elevated.

Wolman disease is the more severe form, manifesting in the first weeks of life with poor feeding, vomiting, and abdominal distention secondary to hepatosplenomegaly; infants usually die within 6 months if untreated.

Cholesteryl ester storage disease is less severe and may not manifest until later in life, even adulthood, at which time hepatomegaly may be detected; premature atherosclerosis, often severe, may develop.

Diagnosis is based on clinical features and DNA analysis and/or detection of acid lipase deficiency in liver biopsy specimens or cultured skin fibroblasts, lymphocytes, or other tissues. Prenatal diagnosis is based on the absence of acid lipase activity in cultured chorionic villi. (Also see testing for suspected inherited disorders of metabolism.)

Until 2015 there was no treatment, and very few infants survived beyond the first year of life. Lysosomal acid lipase deficiency can now be treated with sebelipase alfa, a recombinant form of the deficient enzyme.

Copyright © 2022 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer